<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathophysiology and etiology of edema in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathophysiology and etiology of edema in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathophysiology and etiology of edema in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rudolph P Valentini, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Edema is a clinical condition characterized by an increase in interstitial fluid volume and tissue swelling that can either be localized or generalized. Severe generalized edema is known as anasarca. More localized interstitial fluid collections include ascites and pleural effusions.</p><p>The diagnostic approach to edema is based on a thoughtful approach to the pathogenesis of its formation. Once a diagnosis is established, specific treatment of the underlying disorder can be given. If specific therapy is not available, general treatment, such as optimization of fluid management, can be provided.</p><p>The pediatric disease processes associated with edema and the pathogenesis of edema will be described in this topic review. More detailed discussions of evaluation and management of edema in children as well as the pathophysiology of edema are presented separately. (See  <a class="medical medical_review" href="/d/html/6104.html" rel="external">"Evaluation and management of edema in children"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">OVERVIEW OF PATHOPHYSIOLOGY</span></p><p class="headingAnchor" id="H3"><span class="h2">Normal physiology</span><span class="headingEndMark"> — </span>Edema does not occur in normal subjects, because of the tight balance of hemodynamic forces along the capillary wall and the intact function of the lymphatic system. While capillary hydrostatic pressure favors transcapillary fluid movement into the interstitium, the colloid oncotic pressure across the capillary favors the retention of fluid within the vessel  (<a class="graphic graphic_figure graphicRef55674" href="/d/graphic/55674.html" rel="external">figure 1</a>). Under normal circumstances, these competing forces result in a small net movement of fluid into the interstitium. The lymphatic vessels return this interstitial fluid to the venous system, thereby preventing edema formation.</p><p class="headingAnchor" id="H4"><span class="h2">Pathophysiology of edema</span><span class="headingEndMark"> — </span>The following physiologic processes result in edema formation:</p><p class="bulletIndent1"><span class="glyph">●</span>An alteration in capillary hemodynamics that favors increased movement of fluid from the vascular space into the interstitium</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Failure of interstitial fluid to be returned to the central venous system through the lymphatic vessels</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The retention of dietary or intravenously administered sodium and water by the kidneys, resulting in hypervolemia and increased vascular hydrostatic pressure</p><p></p><p class="headingAnchor" id="H5"><span class="h3">Altered capillary hemodynamics</span><span class="headingEndMark"> — </span>Movement of fluid from the vascular space into the interstitium requires a change in one or more components of the balance of capillary hemodynamics:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased capillary hydrostatic pressure</p><p class="bulletIndent1"><span class="glyph">●</span>Increased capillary permeability</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased capillary oncotic pressure</p><p></p><p class="headingAnchor" id="H6"><span class="h3">Impaired lymphatic transport</span><span class="headingEndMark"> — </span>Failure of the return of interstitial fluid into the central vascular system through the lymphatic system is due to abnormal development, dysfunction, or obstruction of the lymphatic system.</p><p class="headingAnchor" id="H7"><span class="h3">Renal salt and water retention</span><span class="headingEndMark"> — </span>Kidney retention of sodium and water can either be a primary event (as in kidney failure or acute glomerulonephritis [AGN]) or a secondary event resulting from a primary reduction in cardiac output (as in heart failure), or systemic vascular resistance (as in cirrhosis with hepatorenal syndrome). In the latter setting, fluid retention is an appropriate response to return the effective circulating volume toward normal. In these patients, diuretic therapy may have a deleterious effect on systemic hemodynamics even though it reduces the edema.</p><p>The increased salt and water retention leads to hypervolemia and increased capillary hydrostatic pressure (as in AGN).</p><p>The pathophysiology and etiology of edema and regulation of effective circulatory volume are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2309.html" rel="external">"Pathophysiology and etiology of edema in adults"</a> and  <a class="medical medical_review" href="/d/html/2307.html" rel="external">"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)", section on 'Regulation of effective arterial blood volume'</a> and  <a class="medical medical_review" href="/d/html/2307.html" rel="external">"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)", section on 'Edema'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The etiology of edema can be categorized by the mechanism. The following sections review some of the more common causes of edema in children within each category  (<a class="graphic graphic_table graphicRef68106" href="/d/graphic/68106.html" rel="external">table 1</a>).</p><p>Causes of edema in children can also be characterized according to whether they produce generalized or localized edema. Most of the causes summarized below are associated with generalized edema. Heart failure and nephrotic syndrome are examples of causes that produce generalized edema (see <a class="local">'Heart failure'</a> below and <a class="local">'Nephrotic syndrome'</a> below). An example of a common cause of localized edema is venous obstruction either intrinsically from a deep venous thrombosis or extrinsically (eg, venous compression from a tumor). (See <a class="local">'Venous obstruction'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h2">Increased hydrostatic pressure from sodium and water retention</span></p><p class="headingAnchor" id="H10"><span class="h3">Heart failure</span><span class="headingEndMark"> — </span>Heart failure can present with edema due to an increase in venous pressure from sodium and water retention. This produces a parallel rise in capillary hydraulic pressure with increased transcapillary movement of fluid into the interstitial space. The site of edema accumulation is variable and depends on the nature of the cardiac disease:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with impaired left ventricular (LV) function may present with pulmonary, but not peripheral, edema</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pure right ventricular (RV) failure may result in prominent edema in the lower extremities</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiomyopathies, which are associated with impaired function of both the RV and LV, may often lead to the simultaneous onset of pulmonary and peripheral edema</p><p></p><p>Clinical signs of heart failure in the older child include tachycardia, tachypnea, rales or wheezes, gallop rhythm, hepatomegaly, and edema. Infants with heart failure most often present with tachypnea and diaphoresis during feeding, poor feeding, reduced weight gain, lethargy, and irritability. Although facial edema can be seen with RV failure [<a href="#rid1">1</a>], peripheral edema is generally less commonly observed in children with heart failure than in adults. Peripheral edema is unusual in young infants with heart failure [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/14373.html" rel="external">"Heart failure in children: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Acute glomerulonephritis</span><span class="headingEndMark"> — </span>Edema resulting from acute glomerulonephritis (AGN) is typically generalized. The edema is primarily due to kidney sodium and water retention.</p><p>In addition to edema, clinical findings include hypertension, hematuria and proteinuria, cola-colored urine, and/or azotemia. Not all of these features are present in each patient. As an example, cola-colored urine, which is considered a classic feature of AGN, is present in only 30 to 50 percent of children [<a href="#rid3">3</a>]. The finding of red cell casts, even if only one is seen, is virtually diagnostic of glomerulonephritis. (See  <a class="medical medical_review" href="/d/html/6119.html" rel="external">"Glomerular disease: Evaluation in children"</a>.)</p><p>AGN can arise from a number of causes  (<a class="graphic graphic_table graphicRef53697" href="/d/graphic/53697.html" rel="external">table 2</a>) (see  <a class="medical medical_review" href="/d/html/6117.html" rel="external">"Overview of the pathogenesis and causes of glomerulonephritis in children", section on 'Acute nephritic syndrome'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>The most common cause of AGN is postinfectious glomerulonephritis, usually caused by a recent streptococcal infection [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/6118.html" rel="external">"Poststreptococcal glomerulonephritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other causes of primary AGN include immunoglobulin A (IgA) nephropathy, hereditary nephritis (also known as Alport syndrome), and membranoproliferative glomerulonephritis. (See  <a class="medical medical_review" href="/d/html/3112.html" rel="external">"IgA nephropathy: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6093.html" rel="external">"Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)"</a> and  <a class="medical medical_review" href="/d/html/3055.html" rel="external">"Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic diseases associated with glomerulonephritis include systemic lupus erythematosus (SLE), IgA vasculitis (Henoch-Schönlein purpura), antineutrophil cytoplasmic autoantibody-associated diseases such as granulomatosis with polyangiitis and microscopic polyangiitis, and antiglomerular basement membrane disease. (See  <a class="medical medical_review" href="/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification"</a> and  <a class="medical medical_review" href="/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3108.html" rel="external">"Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p>The serum complement component 3 level is a useful diagnostic test in determining the etiology of AGN as the causes of AGN can be classified as either hypocomplementemic or normocomplementemic  (<a class="graphic graphic_table graphicRef53697" href="/d/graphic/53697.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H12"><span class="h3">Renal failure</span><span class="headingEndMark"> — </span>Children with either acute kidney injury or advanced chronic kidney disease can present with edema due to kidney retention of sodium and water. The evaluation and diagnosis of the many different causes of acute or chronic kidney failure are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6126.html" rel="external">"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6134.html" rel="external">"Chronic kidney disease in children: Clinical manifestations and evaluation"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Drugs</span><span class="headingEndMark"> — </span>Antihypertensive agents that are potent vasodilators cause kidney sodium and water retention, leading to increased hydrostatic pressure. These medications include <a class="drug drug_pediatric" data-topicid="12615" href="/d/drug information/12615.html" rel="external">minoxidil</a> and dihydropyridine calcium channel blockers (eg, <a class="drug drug_pediatric" data-topicid="12643" href="/d/drug information/12643.html" rel="external">nifedipine</a>, <a class="drug drug_pediatric" data-topicid="12603" href="/d/drug information/12603.html" rel="external">amlodipine</a>, <a class="drug drug_pediatric" data-topicid="86263" href="/d/drug information/86263.html" rel="external">felodipine</a>, or <a class="drug drug_pediatric" data-topicid="12925" href="/d/drug information/12925.html" rel="external">nicardipine</a>). (See  <a class="medical medical_review" href="/d/html/3832.html" rel="external">"Major side effects and safety of calcium channel blockers"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Increased capillary hydrostatic pressure from obstruction</span></p><p class="headingAnchor" id="H15"><span class="h3">Venous obstruction</span><span class="headingEndMark"> — </span>Localized edema from venous obstruction arises from extrinsic venous compression, thrombosis, or congestion. Regardless of the cause of venous obstruction, the edema that develops occurs distal to the site of obstruction. As an example, symptomatic thrombosis in the inferior vena cava typically presents as swelling of the lower limbs and lower body. By comparison, superior vena cava thrombosis typically presents as swelling of the arm, neck, and head [<a href="#rid5">5</a>]. The severity of the swelling depends on the size of the thrombus and the degree of alternative collateral venous pathways. Often, thrombophlebitis presents with tenderness, swelling, and, occasionally, a palpable cord.</p><p>There are a large number of causes and/or risk factors for venous thrombosis in children (see  <a class="medical medical_review" href="/d/html/5918.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Risk factors, clinical manifestations, and diagnosis", section on 'Risk factors'</a>). They include:</p><p class="bulletIndent1"><span class="glyph">●</span>Venous catheters – Used short term in critical care settings and more chronically in children with chronic diseases such as short gut syndrome (who are parenteral nutritionally dependent) and some hemodialysis patients (temporary vascular access)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital heart disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vasculitis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiphospholipid syndrome (see  <a class="medical medical_review" href="/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome", section on 'Thrombotic events'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperviscosity states (eg, polycythemia)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medications (eg, oral contraceptives)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immobilization</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignancies</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic diseases (eg, nephrotic syndrome) (see  <a class="medical medical_review" href="/d/html/6102.html" rel="external">"Complications of nephrotic syndrome in children", section on 'Thromboembolism'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic predisposing factors including disorders of protein C, protein S, antithrombin III, factor V Leiden, and homocystinuria [<a href="#rid6">6</a>] (see  <a class="medical medical_review" href="/d/html/1354.html" rel="external">"Protein C deficiency"</a> and  <a class="medical medical_review" href="/d/html/1357.html" rel="external">"Protein S deficiency"</a> and  <a class="medical medical_review" href="/d/html/1360.html" rel="external">"Antithrombin deficiency"</a> and  <a class="medical medical_review" href="/d/html/6837.html" rel="external">"Overview of homocysteine"</a>)</p><p></p><p>The pathogenesis and clinical manifestations of venous thromboembolism in children, infants, and neonates are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5918.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Risk factors, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5912.html" rel="external">"Neonatal thrombosis: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Cirrhosis</span><span class="headingEndMark"> — </span>Cirrhosis is defined as irreversible hepatic parenchymal injury with fibrosis of the liver. Children with cirrhosis can develop portal hypertension with an increase in venous pressure below the diseased liver, resulting in ascites and lower extremity edema.</p><p>Although cirrhosis is relatively uncommon in children, the disorder can be caused by genetic disorders (alpha-1 antitrypsin deficiency, cystic fibrosis, Wilson disease), infectious etiologies (viral hepatitis), and structural problems of the biliary tree (biliary atresia, Alagille syndrome). (See  <a class="medical medical_review" href="/d/html/1429.html" rel="external">"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency"</a> and  <a class="medical medical_review" href="/d/html/6367.html" rel="external">"Cystic fibrosis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3626.html" rel="external">"Wilson disease: Epidemiology and pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/5941.html" rel="external">"Approach to evaluation of cholestasis in neonates and young infants"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Decreased capillary oncotic pressure</span><span class="headingEndMark"> — </span>Hypoalbuminemia results in a decrease in capillary oncotic pressure that favors the movement of fluid from the vascular to interstitial compartment. Hypoalbuminemia contributes to edema formation in nephrotic syndrome, liver failure, protein malnutrition, and protein-losing enteropathy.</p><p class="headingAnchor" id="H18"><span class="h3">Protein malnutrition</span><span class="headingEndMark"> — </span>Severe protein malnutrition or kwashiorkor can cause insufficient albumin synthesis, resulting in hypoalbuminemia. This rarely occurs in developed countries. It should be considered in a child with generalized edema, skin rash over the scalp and extremities, and hypopigmentation of the hair (eg, red hair in a child who should have dark hair) [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/5883.html" rel="external">"Malnutrition in children in resource-limited settings: Clinical assessment"</a>.)</p><p class="headingAnchor" id="H19"><span class="h3">Protein-losing enteropathy</span><span class="headingEndMark"> — </span>Children with protein-losing enteropathy have severe protein loss through the gut, resulting in low plasma protein levels (hypoalbuminemia) [<a href="#rid8">8</a>]. Causes include hypertrophic gastritis (Ménétrier disease), milk protein allergy, celiac disease, inflammatory bowel disease, giardiasis, intestinal lymphangiectasia, and right-sided heart dysfunction (post-Fontan procedure) [<a href="#rid9">9,10</a>].</p><p>Stool level of alpha-1 antitrypsin is an excellent screening test for protein-losing enteropathy as alpha-1 antitrypsin is a nondietary, serum protein synthesized in the liver. Its molecular weight of approximately 50 kDa is similar in size to albumin (67 kDa), and it is resistant to intestinal and proteolytic digestion distal to the stomach.</p><p>The clinical manifestations and diagnosis of this disorder are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4769.html" rel="external">"Protein-losing gastroenteropathy"</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Increased capillary permeability</span><span class="headingEndMark"> — </span>Changes in capillary wall permeability are mediated by intrinsic factors, including cytokines (such as tumor necrosis factor and interleukins) and other vasodilators including histamine, bradykinin, prostaglandins, and complement factors (eg, C2a), and extrinsic factors (eg, pit viper venom).</p><p>Generalized edema from increased capillary permeability most often occurs in patients with burns or sepsis. A rare cause is idiopathic systemic capillary leak syndrome. (See  <a class="medical medical_review" href="/d/html/3919.html" rel="external">"Idiopathic systemic capillary leak syndrome"</a>.)</p><p>In addition to generalized edema, a variety of clinical settings (eg, allergic reactions and infections) result in the local release of these inflammatory factors, leading to localized increased capillary permeability and movement of fluid from the vascular space into the interstitium. This condition is referred to as angioedema.</p><p class="headingAnchor" id="H21"><span class="h3">Angioedema</span><span class="headingEndMark"> — </span>Angioedema is associated with swelling of the deep layers of the cutaneous or submucosal tissues due to increased capillary permeability. Affected regions are usually the face, lips, tongue, or larynx.</p><p>Angioedema can be distinguished clinically from generalized edema by the following characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span>More rapid onset of presentation (minutes to hours)</p><p class="bulletIndent1"><span class="glyph">●</span>Asymmetric distribution</p><p class="bulletIndent1"><span class="glyph">●</span>Distribution not in dependent areas</p><p class="bulletIndent1"><span class="glyph">●</span>Involvement of lips, larynx, and bowel</p><p class="bulletIndent1"><span class="glyph">●</span>Association of some forms of angioedema with anaphylaxis</p><p></p><p>Angioedema may be due to allergic reactions (including drug reactions [eg, angiotensin-converting enzyme inhibitors], insect bites, or food) and inherited or acquired deficiency of the C1 esterase inhibitor [<a href="#rid11">11-13</a>]. (See  <a class="medical medical_review" href="/d/html/8099.html" rel="external">"An overview of angioedema: Pathogenesis and causes"</a>.)</p><p>Angioedema, when it involves the airway, is a medical emergency and requires emergent intervention. (See  <a class="medical medical_review" href="/d/html/6383.html" rel="external">"Basic airway management in children"</a>.)</p><p>Hereditary angioedema due to deficiency in C1 inhibitor is quite rare. Affected patients with C1 inhibitor deficiency commonly report a familial history of recurrent episodes of nonpainful, nonpruritic, and nonerythematous angioedema (without urticaria). An acquired form of this disorder also exists in which there is an autoantibody to the C1 inhibitor. This disorder is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8103.html" rel="external">"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis"</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Nephrotic syndrome</span><span class="headingEndMark"> — </span>The nephrotic syndrome is one of the most common causes of generalized edema in childhood. The classic findings of this disorder include marked proteinuria, hypoalbuminemia, and hyperlipidemia, along with generalized edema.</p><p>Edema formation in nephrotic syndrome is a combination of the increased hydrostatic pressure due to primary kidney sodium retention and decreased oncotic pressure due to hypoalbuminemia. The relative role of each process varies from patient to patient. There also appears to be a role for increased capillary permeability mediated by a still unidentified factor or process.</p><p>One proposed mechanism of sodium retention in nephrotic syndrome is marked proteinuria causing conversion of plasminogen into plasmin (a serine protease) within the tubular lumen, which leads to activation of epithelial sodium channel (ENaC) in the cortical collecting duct [<a href="#rid14">14-16</a>]. Further support of the role of serine proteases on ENaC activation comes from evidence that plasmin cleaves the gamma-subunit of ENaC, and, in an experimental model of nephrotic syndrome, volume retention can be inhibited by treatment with the serine protease inhibitor aprotinin [<a href="#rid17">17</a>]. A clinical study of 203 adult nephrotic syndrome patients found that urinary plasminogen-plasmin/creatinine ratios and not albuminuria or 24-hour protein excretion was an independent risk factor for edema formation. This further supports the hypothesis of the importance of urinary plasmin excretion in ENaC activation with resultant sodium retention and edema formation in nephrotic syndrome [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/3044.html" rel="external">"Pathophysiology and treatment of edema in adults with the nephrotic syndrome"</a>.)</p><p>Nephrotic syndrome with an onset prior to three months of age is known as congenital nephrotic syndrome, which is characterized by profound proteinuria and hypoalbuminemia. (See  <a class="medical medical_review" href="/d/html/6137.html" rel="external">"Congenital nephrotic syndrome"</a>.)</p><p>The childhood nephrotic syndrome is associated with a number of glomerular lesions based on kidney histology [<a href="#rid19">19</a>]. They include:</p><p class="bulletIndent1"><span class="glyph">●</span>Minimal change disease is the most common cause of the nephrotic syndrome in children, accounting for 90 percent of cases in children younger than 10 years of age and more than 50 percent of cases in older children. (See  <a class="medical medical_review" href="/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other primary glomerular lesions include focal segmental glomerulosclerosis, mesangial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, and membranous nephropathy [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/3046.html" rel="external">"Minimal change disease: Etiology, clinical features, and diagnosis in adults", section on 'Minimal change variants'</a> and  <a class="medical medical_review" href="/d/html/3055.html" rel="external">"Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary causes include systemic diseases, such as SLE, IgA vasculitis (Henoch-Schönlein purpura), and diabetes and infections, such as human immunodeficiency virus (HIV), hepatitis B virus, and hepatitis C virus [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification"</a> and  <a class="medical medical_review" href="/d/html/14027.html" rel="external">"Overview of kidney disease in patients with HIV"</a> and  <a class="medical medical_review" href="/d/html/3119.html" rel="external">"Kidney disease associated with hepatitis B virus infection"</a> and  <a class="medical medical_review" href="/d/html/3065.html" rel="external">"Overview of kidney disease associated with hepatitis C virus infection"</a>.)</p><p></p><p>The evaluation, diagnosis, and management of the child with nephrotic syndrome are discussed separately. (See  <a class="medical medical_review" href="/d/html/6091.html" rel="external">"Evaluation of proteinuria in children"</a> and  <a class="medical medical_review" href="/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children"</a> and  <a class="medical medical_review" href="/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Lymphatic dysfunction/obstruction</span><span class="headingEndMark"> — </span>Dysfunction and obstruction of the lymphatic vessels result in localized edema as the lymphatic load exceeds the transport capacity of the lymphatic system, resulting in accumulation of protein-rich interstitial fluid [<a href="#rid22">22,23</a>]. A child with lymphedema may have either a primary defect of the lymphatics or a secondary (acquired) defect.</p><p class="headingAnchor" id="H87257370"><span class="h3">Primary lymphedema</span><span class="headingEndMark"> — </span>Primary lymphedema can be divided into the following three different types based on the age of presentation [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphedema precox (77 to 94 percent) – Typically presents at onset of puberty</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital lymphedema (6 to 12 percent) – Presents before two years of age</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphedema tarda (11 percent) – Typically presents after 35 years of age</p><p></p><p class="headingAnchor" id="H798847249"><span class="h4">Lymphedema precox</span><span class="headingEndMark"> — </span>Lymphedema precox is the most common form of primary lymphedema, accounting for 77 to 94 percent of all cases of primary lymphedema [<a href="#rid24">24</a>]. Although it can occur between 2 and 36 years of age, it typically presents at the onset of puberty with unilateral edema, which, in the majority of patients, is limited to the foot and calf. Females are predominantly affected, with a reported 10-fold increase in prevalence in female versus male patients. The pathogenesis is unknown in the majority of cases, but it is speculated that estrogen may play a contributory role because the presentation of this condition most commonly occurs in girls at the onset of puberty.</p><p>Although most cases are sporadic, 10 percent of cases of lymphedema precox are familial (referred to as Meige disease) with an autosomal dominant inheritance pattern [<a href="#rid25">25-28</a>]. Familial lymphedema precox has been associated with a double row of eyelashes (distichiasis) and is referred to as the lymphedema-distichiasis syndrome. A mutation in the <em>FOXC2</em> gene (located at 16q24.3) has been described in families with lymphedema-distichiasis syndrome [<a href="#rid28">28-30</a>]. Mutation of <em>FOXC2</em> results in agenesis of the lymphatic valves and enhanced recruitment of vascular mural cells to lymphatic capillaries [<a href="#rid31">31</a>]. In addition, <em>FOXC2</em> is highly expressed in venous valves, which could explain why approximately one-half of patients with lymphedema-distichiasis have venous insufficiency [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H798847282"><span class="h4">Congenital lymphedema</span><span class="headingEndMark"> — </span>Congenital lymphedema (presentation before two years of age) is due to a congenital and/or inherited condition associated with pathologic development of the lymphatic vessels, which may include the following abnormalities [<a href="#rid23">23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced numbers of lymphatic collectors</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphatic hypoplasia (decreased diameter of the lymphatic vessels)</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphatic hyperplasia (increased diameter of lymphatic collectors)</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphatic aplasia (absence of lymphatic system components)</p><p class="bulletIndent1"><span class="glyph">●</span>Lymph node fibrosis</p><p></p><p>The following congenital conditions are associated with primary lymphedema in children:</p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary congenital lymphedema – Hereditary congenital lymphedema (primary congenital lymphedema, hereditary lymphedema type I, or Milroy disease) is transmitted as an autosomal dominant trait [<a href="#rid33">33</a>]. Affected individuals usually develop lymphedema in both lower extremities soon after birth, but it typically does not worsen over time. Most affected families carry a missense mutation in the gene encoding VEGFR-3 (expressed in the lymphatic endothelium), resulting in impaired lymphatic development [<a href="#rid34">34-37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cholestasis-lymphedema syndrome – Cholestasis-lymphedema syndrome (Aagenaes syndrome, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F214900&amp;token=tEpDslnpc0F0kICl%2Fz7sFZpszKvOtG3bo7mRUx02%2BlbRqOKLgkSVppoYlIR2nk9h&amp;TOPIC_ID=6096" target="_blank">MIM 214900</a>) is an autosomal recessive disorder characterized by congenital lymphatic hypoplasia and recurrent cholestasis [<a href="#rid38">38</a>]. The lymphedema characteristically involves the legs of infants. The syndrome is caused by pathogenic variants in the 5' untranslated region of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F214900&amp;token=tEpDslnpc0F0kICl%2Fz7sFZpszKvOtG3bo7mRUx02%2BlbRqOKLgkSVppoYlIR2nk9h&amp;TOPIC_ID=6096" target="_blank"><i>UNC45A</i></a>, which is associated with aberrant localization of two hepatobiliary transport proteins [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other conditions – Other conditions associated with congenital lymphedema include Noonan syndrome; Turner syndrome; and trisomy 13, 18, and 21. These conditions are discussed separately. (See  <a class="medical medical_review" href="/d/html/5832.html" rel="external">"Causes of short stature", section on 'Noonan syndrome'</a> and  <a class="medical medical_review" href="/d/html/7391.html" rel="external">"Clinical manifestations and diagnosis of Turner syndrome"</a> and  <a class="medical medical_review" href="/d/html/452.html" rel="external">"Congenital cytogenetic abnormalities", section on 'Trisomy 18 syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H798847289"><span class="h4">Lymphedema tarda</span><span class="headingEndMark"> — </span>Lymphedema tarda presents after 35 years of age. It also occurs more commonly in females and affects the lower extremities.</p><p class="headingAnchor" id="H87258358"><span class="h3">Secondary lymphedema</span><span class="headingEndMark"> — </span>Lymphedema attributable to an acquired dysfunction of the lymphatic system may be caused by a wide range of conditions, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Cancer and its treatment</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection – Globally, lymphatic filariasis caused by the nematode <em>Wuscheria</em> <em>bancrofti</em> is the most common cause of acquired pediatric lymphedema [<a href="#rid40">40</a>] (see  <a class="medical medical_review" href="/d/html/5680.html" rel="external">"Lymphatic filariasis: Treatment and prevention"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune diseases – Lymphatic involvement can also occur in a variety of autoimmune diseases such as sarcoidosis, juvenile idiopathic arthritis, and Crohn disease [<a href="#rid41">41,42</a>] (see  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a> and  <a class="medical medical_review" href="/d/html/6414.html" rel="external">"Polyarticular juvenile idiopathic arthritis: Clinical manifestations, diagnosis, and complications"</a>)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology of edema</strong> – Edema formation results from one or a combination of the following processes (see <a class="local">'Pathophysiology of edema'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An alteration in capillary hemodynamics that favors the movement of fluid from the vascular space into the interstitium. These alterations include increased capillary hydrostatic pressure, decreased capillary oncotic pressure, and increased capillary permeability  (<a class="graphic graphic_figure graphicRef55674" href="/d/graphic/55674.html" rel="external">figure 1</a>). (See <a class="local">'Altered capillary hemodynamics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A defective lymphatic system that fails to return interstitial fluid to the central venous system. This can occur due to maldevelopment, injury, or obstruction of the lymphatic system. (See <a class="local">'Impaired lymphatic transport'</a> above and <a class="local">'Lymphatic dysfunction/obstruction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The retention of dietary or intravenously administered sodium and water by the kidneys. (See <a class="local">'Renal salt and water retention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of edema in children</strong> – Causes of edema in children can be categorized according to the mechanism  (<a class="graphic graphic_table graphicRef68106" href="/d/graphic/68106.html" rel="external">table 1</a>). Understanding and identifying the underlying process and cause of the edema can be helpful in the management of these patients. (See <a class="local">'Etiology'</a> above and  <a class="medical medical_review" href="/d/html/6104.html" rel="external">"Evaluation and management of edema in children"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Lamb FS. Heart failure. In: Saunders Manual of Pediatric Practice, Finberg L (Ed), WB Saunders, Philadelphia 1998. p.600.</li><li class="breakAll">Gewitz MH, Woolf PK. Cardiac emergencies. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.717.</li><li class="breakAll">Brouhard BH, et al. Acute postinfectious glomerulonephritis. In: Pediatric Kidney Disease, Edelmann CM (Ed), Little, Brown and Company, Boston 1992. p.1199.</li><li class="breakAll">Blowey DL. Acute glomerulonephritis. In: Saunders Manual of Pediatric Practice, Finberg L (Ed), WB Saunders, Philadelphia 1998. p.688.</li><li><a class="nounderline abstract_t">Issa PY, Brihi ER, Janin Y, Slim MS. Superior vena cava syndrome in childhood: report of ten cases and review of the literature. Pediatrics 1983; 71:337.</a></li><li class="breakAll">Hagani A. Thrombophilia. In: Saunders Manual of Pediatric Practice, Finberg L (Ed), WB Saunders Company, Philadelphia 1998. p.431.</li><li><a class="nounderline abstract_t">Chase HP, Kumar V, Caldwell RT, O'Brien D. Kwashiorkor in the United States. Pediatrics 1980; 66:972.</a></li><li><a class="nounderline abstract_t">Martin PY, Ginès P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339:533.</a></li><li class="breakAll">Brasitus TA. Protein-losing gastroenteropathy. In: Gastrointestinal Disease: Pathophysiology, Diagnosis, Management, Sleisenger JS (Ed), WB Saunders, Philadelphia 1993. p.1027.</li><li class="breakAll">Thomas DW, et al. Protein-losing enteropathy. In: Principles and Practice of Pediatrics, Oski CD, Feigin RD, Warshaw JB (Eds), J.B. Lippincott Company, Philadelphia 1990. p.1722.</li><li><a class="nounderline abstract_t">Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001; 14:963.</a></li><li><a class="nounderline abstract_t">Zingale LC, Beltrami L, Zanichelli A, et al. Angioedema without urticaria: a large clinical survey. CMAJ 2006; 175:1065.</a></li><li><a class="nounderline abstract_t">Davis RS, Vandewalker ML, Hutcheson PS, Slavin RG. Facial angioedema in children due to ladybug (Harmonia axyridis) contact: 2 case reports. Ann Allergy Asthma Immunol 2006; 97:440.</a></li><li><a class="nounderline abstract_t">Svenningsen P, Bistrup C, Friis UG, et al. Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol 2009; 20:299.</a></li><li><a class="nounderline abstract_t">Rondon-Berrios H. [New insights into the pathophysiology of oedema in nephrotic syndrome]. Nefrologia 2011; 31:148.</a></li><li><a class="nounderline abstract_t">Pearce D, Soundararajan R, Trimpert C, et al. Collecting duct principal cell transport processes and their regulation. Clin J Am Soc Nephrol 2015; 10:135.</a></li><li><a class="nounderline abstract_t">Bohnert BN, Menacher M, Janessa A, et al. Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome. Kidney Int 2018; 93:159.</a></li><li><a class="nounderline abstract_t">Chen JL, Wang L, Yao XM, et al. Association of Urinary Plasminogen-Plasmin with Edema and Epithelial Sodium Channel Activation in Patients with Nephrotic Syndrome. Am J Nephrol 2019; 50:92.</a></li><li class="breakAll">Valentini RP, Smoyer WE. Nephrotic Syndrome. In: Clinical Pediatric Nephrology, 2nd ed, Kher KK, Schnaper HW, Makker SP (Eds), Informa Healthcare, London 2007. p.155.</li><li><a class="nounderline abstract_t">McAdams AJ, Valentini RP, Welch TR. The nonspecificity of focal segmental glomerulosclerosis. The defining characteristics of primary focal glomerulosclerosis, mesangial proliferation, and minimal change. Medicine (Baltimore) 1997; 76:42.</a></li><li class="breakAll">Olson JL, Schwartz MM. The Nephrotic Syndrome: Minimal change disease. Focal segmental glomerulosclerosis, and miscellaneous causes. In: Heptinstall's pathology of the kidney, Jennette JL, Schwartz MM, Silva FG (Eds), Lippincott-Raven, Philadelphia 1998. p.187.</li><li><a class="nounderline abstract_t">Rockson SG. Lymphedema. Am J Med 2001; 110:288.</a></li><li><a class="nounderline abstract_t">Lawenda BD, Mondry TE, Johnstone PA. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin 2009; 59:8.</a></li><li><a class="nounderline abstract_t">Szuba A, Rockson SG. Lymphedema: classification, diagnosis and therapy. Vasc Med 1998; 3:145.</a></li><li><a class="nounderline abstract_t">Lewis JM, Wald ER. Lymphedema praecox. J Pediatr 1984; 104:641.</a></li><li><a class="nounderline abstract_t">Harel L, Amir J, Nussinovitch M, et al. Lymphedema praecox seen as isolated unilateral arm involvement: case report and review of the literature. J Pediatr 1997; 130:492.</a></li><li><a class="nounderline abstract_t">Wheeler ES, Chan V, Wassman R, et al. Familial lymphedema praecox: Meige's disease. Plast Reconstr Surg 1981; 67:362.</a></li><li><a class="nounderline abstract_t">Connell F, Brice G, Mortimer P. Phenotypic characterization of primary lymphedema. Ann N Y Acad Sci 2008; 1131:140.</a></li><li><a class="nounderline abstract_t">Finegold DN, Kimak MA, Lawrence EC, et al. Truncating mutations in FOXC2 cause multiple lymphedema syndromes. Hum Mol Genet 2001; 10:1185.</a></li><li><a class="nounderline abstract_t">Fang J, Dagenais SL, Erickson RP, et al. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet 2000; 67:1382.</a></li><li><a class="nounderline abstract_t">Petrova TV, Karpanen T, Norrmén C, et al. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med 2004; 10:974.</a></li><li><a class="nounderline abstract_t">Mellor RH, Brice G, Stanton AW, et al. Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb. Circulation 2007; 115:1912.</a></li><li><a class="nounderline abstract_t">Warren AG, Brorson H, Borud LJ, Slavin SA. Lymphedema: a comprehensive review. Ann Plast Surg 2007; 59:464.</a></li><li><a class="nounderline abstract_t">Evans AL, Brice G, Sotirova V, et al. Mapping of primary congenital lymphedema to the 5q35.3 region. Am J Hum Genet 1999; 64:547.</a></li><li><a class="nounderline abstract_t">Ferrell RE, Levinson KL, Esman JH, et al. Hereditary lymphedema: evidence for linkage and genetic heterogeneity. Hum Mol Genet 1998; 7:2073.</a></li><li><a class="nounderline abstract_t">Karkkainen MJ, Ferrell RE, Lawrence EC, et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 2000; 25:153.</a></li><li><a class="nounderline abstract_t">Mäkinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001; 7:199.</a></li><li><a class="nounderline abstract_t">Bull LN, Roche E, Song EJ, et al. Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q. Am J Hum Genet 2000; 67:994.</a></li><li><a class="nounderline abstract_t">Almaas R, Atneosen-Åsegg M, Ytre-Arne ME, et al. Aagenaes syndrome/lymphedema cholestasis syndrome 1 is caused by a founder variant in the 5'-untranslated region of UNC45A. J Hepatol 2023; 79:945.</a></li><li><a class="nounderline abstract_t">Witt C, Ottesen EA. Lymphatic filariasis: an infection of childhood. Trop Med Int Health 2001; 6:582.</a></li><li><a class="nounderline abstract_t">Athreya BH, Ostrov BE, Eichenfield AH, Goldsmith DP. Lymphedema associated with juvenile rheumatoid arthritis. J Rheumatol 1989; 16:1338.</a></li><li><a class="nounderline abstract_t">Murphy MJ, Kogan B, Carlson JA. Granulomatous lymphangitis of the scrotum and penis. Report of a case and review of the literature of genital swelling with sarcoidal granulomatous inflammation. J Cutan Pathol 2001; 28:419.</a></li></ol></div><div id="topicVersionRevision">Topic 6096 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lamb FS. Heart failure. In: Saunders Manual of Pediatric Practice, Finberg L (Ed), WB Saunders, Philadelphia 1998. p.600.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Gewitz MH, Woolf PK. Cardiac emergencies. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.717.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Brouhard BH, et al. Acute postinfectious glomerulonephritis. In: Pediatric Kidney Disease, Edelmann CM (Ed), Little, Brown and Company, Boston 1992. p.1199.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Blowey DL. Acute glomerulonephritis. In: Saunders Manual of Pediatric Practice, Finberg L (Ed), WB Saunders, Philadelphia 1998. p.688.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6828340" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Superior vena cava syndrome in childhood: report of ten cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6828340" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Superior vena cava syndrome in childhood: report of ten cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7454490" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Kwashiorkor in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709047" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709047" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709047" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11587165" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060655" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Angioedema without urticaria: a large clinical survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17069094" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Facial angioedema in children due to ladybug (Harmonia axyridis) contact: 2 case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19073825" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Plasmin in nephrotic urine activates the epithelial sodium channel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21461007" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : [New insights into the pathophysiology of oedema in nephrotic syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24875192" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Collecting duct principal cell transport processes and their regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29042083" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31269481" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Association of Urinary Plasminogen-Plasmin with Edema and Epithelial Sodium Channel Activation in Patients with Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31269481" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Association of Urinary Plasminogen-Plasmin with Edema and Epithelial Sodium Channel Activation in Patients with Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9064487" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The nonspecificity of focal segmental glomerulosclerosis. The defining characteristics of primary focal glomerulosclerosis, mesangial proliferation, and minimal change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9064487" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The nonspecificity of focal segmental glomerulosclerosis. The defining characteristics of primary focal glomerulosclerosis, mesangial proliferation, and minimal change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11239847" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Lymphedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19147865" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9796078" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Lymphedema: classification, diagnosis and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6371208" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lymphedema praecox.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9063433" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lymphedema praecox seen as isolated unilateral arm involvement: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7232571" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Familial lymphedema praecox: Meige's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18519967" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Phenotypic characterization of primary lymphedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11371511" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Truncating mutations in FOXC2 cause multiple lymphedema syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11078474" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15322537" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17372167" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901744" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Lymphedema: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9973292" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mapping of primary congenital lymphedema to the 5q35.3 region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817924" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hereditary lymphedema: evidence for linkage and genetic heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10835628" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11175851" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10968776" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37328071" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Aagenaes syndrome/lymphedema cholestasis syndrome 1 is caused by a founder variant in the 5'-untranslated region of UNC45A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11555425" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Lymphatic filariasis: an infection of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2681759" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Lymphedema associated with juvenile rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11493380" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Granulomatous lymphangitis of the scrotum and penis. Report of a case and review of the literature of genital swelling with sarcoidal granulomatous inflammation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
